Discussing Psychedelics with Patients: Answering your Legal Questions

*Register by completing this form. You'll be emailed with a calendar invitation.

Show this section for Logged Out users

Event - Thursday, June 29th at 5 pm Pacific, 8 pm Eastern >> Sign up >>


Join Us For an EXCLUSIVE Panel Discussion for Members of The Psychedelic Medicine Association:

You are unauthorized to view this page.

"Discussing Psychedelics with Patients: Answering your Legal Questions"

Panel Moderator:

Lynn Marie Morski, MD, ESQ

President - Psychedelic Medicine Association


Sean McAllister, Esq.

McAllister Garfield, P.C.

Sean McAllister is one of nation’s leading drug policy reform lawyers. Sean has pioneered legal and business strategies for entrepreneurs in the cannabis, hemp, recycling, and psychedelics spaces. His work in the psychedelic space has included advising religious organizations on their rights to use psychedelics as sacraments, seeking DEA licensure for a public company manufacturing psilocybin for clinical trials, helping psychedelic assisted therapists understand the risks of these activities, advising on what is legal in decriminalized cities, and understanding new state regulatory laws like Oregon’s Measure 109. Sean’s work on drug policy reform goes back 25 years, starting on the Colorado Prison Moratorium Campaign in the mid-1990s. From 2004- 2012, Sean served the chair of the Board of Directors of the organization that ran the Colorado recreational marijuana legalization campaign that voters ultimately approved. Sean has also worked on broader drug policy reform issues as a member of the Colorado Commission on Criminal and Juvenile Justice. Sean is an appointed member of the Denver Psilocybin Mushroom Policy Review Panel, which was the first ballot initiative in the U.S. decriminalize the possession, cultivation and storage of psilocybin. Sean has been a legal advisor to other cities and states considering psychedelic decriminalization efforts, including the Decriminalize California campaign in 2020 and Decriminalize Seattle in 2021. Sean is a member of Chacruna’s Council for the Protection of Sacred Plants.

Serena Wu, Esq.

Plant Medicine Law Group

Serena is a Chinese-American lawyer, born in Hainan and raised in Los Angeles. She has a J.D. from Harvard University Law School and a B.A. in Media Studies from University of California, Berkeley. Serena began her legal career at Davis Polk & Wardwell LLP in New York City as a litigation associate, with a focus on commercial and securities litigation, regulatory enforcement and compliance. She has experience overseeing e-discovery processes, conducting internal investigations for clients in the financial sector, engaging in motion practice, and designing a regulatory compliance tracking system. In her pro bono practice, she represented indigent criminal defendants in challenging New York’s cash bail, plaintiffs in a wage-and-hour dispute, and a mother in a family court trial. Serena is deeply committed to increasing equitable access to alternative healing, including psychedelic plant medicines. She is the founder of Women in Psychedelics, an Instagram account that showcases the contributions, voices, and experiences of women in the psychedelics space, and Asian Psychedelics Society (“APS”), a group dedicated to discussions about psychedelics and mental health in the AAPI community.

MDMA-assisted therapy just made the front page of the NY Times. Psilocybin-assisted therapy was featured on 60 Minutes. So if your patients haven’t already started asking about psychedelics, they will soon.

And what will you say? Or perhaps the bigger question is: what can you *legally* say?

That’s why we’ve assembled a panel of legal experts in the psychedelic field to answer the myriad of questions you may have regarding what you can and can’t discuss with patients about these substances that are still illegal federally. 

From the legality of discussing illegal substances to whether clinicians can refer to psychedelic therapists, our legal experts are here to answer your questions as we collectively enter a new frontier in medicine. There will be ample time for audience Q and A at the end, so you’ll get to interact with the panelists directly!

So please join us for this live panel discussion on Thursday, May 27th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.

Hope to see you all on the 27th!

You can find the Psychedelic Medicine Association on Twitter at @Psychedelic_Med, LinkedIn and on Facebook.